PortalPublikationenClinical importance and potential use of small molecule inhi...

Clinical importance and potential use of small molecule inhibitors of focal adhesion kinase.

Standard

Clinical importance and potential use of small molecule inhibitors of focal adhesion kinase. / Schultze, Alexander; Fiedler, Walter.

in: ANTI-CANCER AGENT ME, Jahrgang 11, Nr. 7, 7, 2011, S. 593-599.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Schultze, A & Fiedler, W 2011, 'Clinical importance and potential use of small molecule inhibitors of focal adhesion kinase.', ANTI-CANCER AGENT ME, Jg. 11, Nr. 7, 7, S. 593-599. <http://www.ncbi.nlm.nih.gov/pubmed/21787277?dopt=Citation>

APA

Schultze, A., & Fiedler, W. (2011). Clinical importance and potential use of small molecule inhibitors of focal adhesion kinase. ANTI-CANCER AGENT ME, 11(7), 593-599. [7]. http://www.ncbi.nlm.nih.gov/pubmed/21787277?dopt=Citation

Vancouver

Schultze A, Fiedler W. Clinical importance and potential use of small molecule inhibitors of focal adhesion kinase. ANTI-CANCER AGENT ME. 2011;11(7):593-599. 7.

Bibtex

@article{165c68d2e3ef4ce699be1fe20e414ac9,
title = "Clinical importance and potential use of small molecule inhibitors of focal adhesion kinase.",
abstract = "Since its first description Focal Adhesion Kinase (FAK), a cytoplasmatic tyrosine kinase, has been implicated in the formation and progression of solid and liquid malignant tumors. Therefore orally available selective small molecule inhibitors of FAK have been developed, three of them (PF-562-271, PF-04554878 and GSK2256098) are already in clinical testing. This review discusses the recent data obtained from these Phase 1 trials. We also discuss available data on the mechanisms of action of these inhibitors in carcinogenesis and demonstrate that FAK plays an important role in neoangiogenesis which is a crucial step in cancer growth.",
author = "Alexander Schultze and Walter Fiedler",
year = "2011",
language = "English",
volume = "11",
pages = "593--599",
journal = "ANTI-CANCER AGENT ME",
issn = "1871-5206",
publisher = "Bentham Science Publishers B.V.",
number = "7",

}

RIS

TY - JOUR

T1 - Clinical importance and potential use of small molecule inhibitors of focal adhesion kinase.

AU - Schultze, Alexander

AU - Fiedler, Walter

PY - 2011

Y1 - 2011

N2 - Since its first description Focal Adhesion Kinase (FAK), a cytoplasmatic tyrosine kinase, has been implicated in the formation and progression of solid and liquid malignant tumors. Therefore orally available selective small molecule inhibitors of FAK have been developed, three of them (PF-562-271, PF-04554878 and GSK2256098) are already in clinical testing. This review discusses the recent data obtained from these Phase 1 trials. We also discuss available data on the mechanisms of action of these inhibitors in carcinogenesis and demonstrate that FAK plays an important role in neoangiogenesis which is a crucial step in cancer growth.

AB - Since its first description Focal Adhesion Kinase (FAK), a cytoplasmatic tyrosine kinase, has been implicated in the formation and progression of solid and liquid malignant tumors. Therefore orally available selective small molecule inhibitors of FAK have been developed, three of them (PF-562-271, PF-04554878 and GSK2256098) are already in clinical testing. This review discusses the recent data obtained from these Phase 1 trials. We also discuss available data on the mechanisms of action of these inhibitors in carcinogenesis and demonstrate that FAK plays an important role in neoangiogenesis which is a crucial step in cancer growth.

M3 - SCORING: Journal article

VL - 11

SP - 593

EP - 599

JO - ANTI-CANCER AGENT ME

JF - ANTI-CANCER AGENT ME

SN - 1871-5206

IS - 7

M1 - 7

ER -